Skip to main content

Security report for biogen.hr

Biogen · Healthcare · Croatia

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

79/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen.hr is the Croatian localized website of Biogen, a leading global biotechnology company specializing in innovative therapies for complex neurological and rare diseases. The website presents a professional and well-structured digital presence, leveraging Adobe Experience Manager CMS and hosted on AWS infrastructure. It features comprehensive cookie consent management via Cookiebot and integrates Google Analytics with IP anonymization, demonstrating a commitment to privacy compliance. While the site lacks explicit published security or incident response policies, it employs secure HTTPS protocols and best practices such as HttpOnly cookies. The content is targeted at a general audience in Croatia, focusing on healthcare professionals, patients, and stakeholders interested in Biogen's therapeutic areas and corporate responsibility. Overall, the website reflects a mature, trustworthy, and professional digital asset aligned with Biogen's global brand.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen.hr

This scan found 18 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
62
Security headers
95
Email security
60
DNS health
75
Network security
100
GDPR outside view
83
Average
79

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen operates as a large healthcare biotechnology company with a strong market position in neurological and rare disease therapies. The Croatian site supports regional engagement and provides information on therapeutic areas, corporate responsibility, and employment opportunities. The business model centers on research, development, and commercialization of specialty pharmaceuticals. The website's linkage to multiple country-specific Biogen domains indicates a broad international presence. The absence of direct contact emails or phone numbers suggests reliance on contact forms and controlled communication channels. The site’s GDPR compliance and cookie management reflect adherence to European data protection standards.

Security posture

The website demonstrates a solid security posture with HTTPS enforced, secure cookie attributes, and privacy-conscious analytics implementation. However, it lacks publicly available dedicated security policies, incident response information, or vulnerability disclosure mechanisms. No security headers were explicitly detected in the provided data, representing an area for improvement. The cookie consent mechanism is robust and user-friendly, supporting granular user choices. Overall, the security maturity is good but could be enhanced by publishing formal security and incident response documentation and implementing additional HTTP security headers.

Recommendations

  1. Publish a dedicated security policy page outlining security practices and commitments.
  2. Implement and publicize an incident response plan and contact channels for security issues.
  3. Add HTTP security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to enhance protection.
  4. Provide direct company contact emails and phone numbers for improved transparency and user trust.
  5. Regularly review and update cookie and privacy policies to maintain compliance with evolving regulations.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen
Description
Biogen je vodeća globalna biotehnološka tvrtka koja prednjači u području znanosti i pokretač je inovacija za složene i teške bolesti. Biogen unapređuje niz potencijalnih terapija u neuroznanosti, neuropsihijatriji, specijaliziranoj imunologiji i rijetkim bolestima i ostaje snažno usredotočen na svrhu služenja čovječanstvu kroz znanost, uz istovremeno zalaganje za zdraviji, održiviji i pravedniji svijet.
Key services
development of therapies for multiple sclerosis, therapies for spinal muscular atrophy, therapies targeting Alzheimer’s disease pathology
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.6.4, Adobe Helix RUM, Cookiebot, Google Tag Manager, Google Analytics
Frameworks
Adobe Experience Manager (AEM)
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • HttpOnly and Secure cookies used
  • Cookie consent banner with granular controls
  • IP anonymization enabled for Google Analytics

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Comprehensive cookie consent mechanism implemented with Cookiebot.
  3. Use of Google Analytics with IP anonymization indicates privacy awareness.
  4. No direct company emails or phone numbers found in visible content; contact form present.
  5. No explicit security or incident response policies published.
  6. Website uses Adobe Experience Manager CMS and AWS hosting infrastructure.
  7. Content is professional, healthcare focused, and localized for Croatia.
  8. No suspicious or malicious content detected.
Technical notes

Notes

The website is built on Adobe Experience Manager CMS, a robust enterprise platform, and hosted on AWS infrastructure, ensuring scalability and reliability. The tech stack includes modern JavaScript libraries like jQuery 3.6.4 and Adobe Helix RUM for performance monitoring. Cookiebot manages cookie consent effectively, integrating with Google Tag Manager and Google Analytics with IP anonymization for privacy. The site is mobile optimized with responsive design and good SEO practices. Performance is moderate, with potential for optimization. Accessibility is basic and could be improved to meet higher standards. Overall, the technical implementation supports a professional and compliant web presence.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen.hr. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen.hr.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.